Switching to bictegravir/ emtricitabine/tenofovir alafenamide plus darunavir/cobicistat in heavily antiretroviralexperienced, virologically suppressed HIV-infected adults receiving complex regimens: 48-week analysis

被引：0

作者：

Podzamczer, D. ^{[1
]}

Imaz, A. ^{[2
]}

Lopez-Lirola, A. ^{[3
]}

Knobel, H. ^{[4
]}

Masia, M. ^{[5
]}

Fanciulli, C. ^{[6
]}

Hernadez, C. ^{[7
]}

Lagarde, M. ^{[8
]}

Gutierrez, A. ^{[9
]}

Curran, A. ^{[10
]}

Morano, L. ^{[11
]}

Montero-Alonso, M. ^{[12
]}

Troya, J. ^{[13
]}

Rigo, R.

Casadella, M. ^{[14
]}

Navarro-Alcaraz, A. ^{[14
]}

Ardila, F.

Parera, M. ^{[14
]}

Bernal, E. ^{[15
]}

Echeverria, P. ^{[16
]}

Estrada, V. ^{[17
]}

Hidalgo-Tenorio, C. ^{[18
]}

Macias, J. ^{[19
]}

Priet, P. ^{[20
]}

Portilla, J. ^{[21
]}

Valencia, E. ^{[22
]}

Vivancos, M. J. ^{[23
]}

Rivero, A.

机构：

[1] Fight Infect Fdn, Badalona, Spain

[2] Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain

[3] Hosp Univ Canarias, San Cristobal la Laguna, Spain

[4] Hosp Univ Gen Elche, Elche, Spain

[5] Hosp Gen Univ Gregorio Maran, Inst Invest Sanitaria Gregorio Maran IiSGM, Ctr Invest Biomed Red Enfermedades Infecc, Madrid, Spain

[6] Hosp Principe Asturias, Alcala De Henares, Spain

[7] Hosp Univ 12 Octubre, Madrid, Spain

[8] Hosp Univ Princesa, Madrid, Spain

[9] Hosp Univ Vall dHebron, Barcelona, Spain

[10] Hosp Univ Alvaro Cunqueiro, Vigo, Spain

[11] Hosp Univ Politecn La Fe, Valencia, Spain

[12] Hosp Univ Infanta Leonor, Madrid, Spain

[13] IrsiCaixa Inst Recerca SIDA, Badalona, Spain

[14] Hosp Univ Reina Sofia, Murcia, Spain

[15] Hosp Badalona Germans Trias & Pujol, Fight Infect Fdn, Badalona, Spain

[16] Hosp Clin San Carlos, Madrid, Spain

[17] Hosp Univ Virgen de Ias Nieves, Granada, Spain

[18] Univ Seville, IBiS,Hosp Univ Virgen de Valme, Inst Biomed Sevilla,Unidad Enfermedades Infecc &, CIBERINFEC,Dept Med,CSIC, Seville, Spain

[19] Hosp Univ Santa Creu & St Pau, Barcelona, Spain

[20] Hosp Gen Univ Alicante, Alicante, Spain

[21] Hosp Univ La Paz, Madrid, Spain

[22] Hosp Univ Ramon y Cajal, Madrid, Spain

[23] Univ Cordoba UCO, Hosp Univ Reina Sofia, Inst Maimonides Invest Biomed Cordoba IMIBIC, ISCIII CIBER Enfermedades Infecc Inst Salud Carlo, Cordoba, Spain

来源：

HIV MEDICINE | 2023年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

EACS2023:

引用

下载

页码：310 / 311

页数：2

共 50 条

[21] THE 48-WEEK EFFICACY AND SAFETY OF SWITCHING TO FIXED-DOSE EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF IN HIV-1-INFECTED PATIENTS RECEIVING HAART
Carlevari, M.
DeJesus, E.
Pozniak, A.
Gallant, J.
Arribas, J.
Lazzarin, A.
Zhou, Y.
Cheng, A.
Warren, D.
Enejosa, J.
INFECTION, 2009, 37 : 62 - 62
[22] Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis
Gallien, S.
Massetti, M.
Flandre, P.
Leleu, H.
Descamps, D.
Lazaro, E.
HIV MEDICINE, 2018, 19 (08) : 559 - 571
[23] Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Eron, Joseph J.
Orkin, Chloe
Cunningham, Douglas
Pulido, Federico
Post, Frank A.
De Wit, Stephane
Lathouwers, Erkki
Hufkens, Veerle
Jezorwski, John
Petrovic, Romana
Brown, Kimberley
Van Landuyt, Erika
Opsomer, Magda
De Wit, S.
Florence, E.
Moutschen, M.
Van Wijngaerden, E.
Vandekerckhove, L.
Vandercam, B.
Brunetta, J.
Conway, B.
Klein, M.
Murphy, D.
Rachlis, A.
Shafran, S.
Walmsley, S.
Ajana, F.
Cotte, L.
Girardy, P. -M.
Katlama, C.
Molina, J. -M.
Poizot-Martin, I.
Raffi, F.
Rey, D.
Reynes, J.
Teicher, E.
Yazdanpanah, Y.
Gasiorowski, J.
Halota, W.
Horban, A.
Piekarska, A.
Witor, A.
Arribas, J. R.
Perez-Valero, I.
Berenguer, J.
Casado, J.
Gatell, J. M.
Gutierrez, F.
Galindo, M. J.
Gutierrez, M. D. M.
ANTIVIRAL RESEARCH, 2019, 170
[24] Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting
Lombardi, Francesca
Belmonti, Simone
Moschese, Davide
Fabbiani, Massimiliano
Borghetti, Alberto
Ciccullo, Arturo
Visconti, Elena
Di Giambenedetto, Simona
HIV RESEARCH & CLINICAL PRACTICE, 2022, 23 (01) : 28 - 36
[25] Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1:48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
Daar, Eric S.
Dejesus, Edwin
Ruane, Peter
Crofoot, Gordon
Oguchi, Godson
Creticos, Catherine
Rockstroh, Juergen K.
Molina, Jean-Michel
Koenig, Ellen
Liu, Ya-Pei
Custodio, Joseph
Andreatta, Kristen
Graham, Hiba
Cheng, Andrew
Martin, Hal
Quirk, Erin
LANCET HIV, 2018, 5 (07): : E347 - E356
[26] Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Molina, Jean-Michel
Ward, Douglas
Brar, Indira
Mills, Anthony
Stellbrink, Hans Juergen
Lopez-Cortes, Luis
Ruane, Peter
Podzamczer, Daniel
Brinson, Cynthia
Custodio, Joseph
Liu, Hui
Andreatta, Kristen
Martin, Hal
Cheng, Andrew
Quirk, Erin
LANCET HIV, 2018, 5 (07): : E357 - E365
[27] Real-world data on persons living with HIV (PLWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) while virologically suppressed: 96-week data from the Icona cohort
Monforte, A. d'Arminio
Tavelli, A.
Cingolani, A.
Taramasso, L.
Mussini, C.
Piconi, S.
Calcagno, A.
Orofino, G.
Cicalini, S.
Castagna, A.
Ceccherini-Silberstein, F.
Gori, A.
Guaraldi, G.
Antinori, A.
HIV MEDICINE, 2023, 24 : 157 - 159
[28] SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen
Campo, R.
DeJesus, E.
Bredeek, U. F.
Henry, K.
Khanlou, H.
Logue, K.
Brinson, C.
Benson, P.
Dau, L.
Wang, H.
White, K.
Flaherty, J.
Fralich, T.
Guyer, B.
Piontkowsky, D.
CLINICAL INFECTIOUS DISEASES, 2013, 56 (11) : 1637 - 1645
[29] Real-world clinical outcomes of HIV-1 virologically suppressed adults on bictegravir/emtricitabine/tenofovir alafenamide who switched to long-acting intramuscular cabotegravir plus rilpivirine at 12, 24, and 48-weeks
Nasser, K.
Valentin, A. -M.
Ramgopal, M.
HIV MEDICINE, 2023, 24 : 161 - 162
[30] Strategic simplification: the efficacy and safety of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus darunavir (DRV) in treatment-experienced HIV-1 infected adults (NCT01968551)
Huhn, G.
Gallant, J.
Wilkin, T.
Callebaut, C.
Fordyce, M.
Das, M.
Mccallister, S.
Yau, S.
HIV MEDICINE, 2016, 17 : 15 - 15

← 1 2 3 4 5 →